They asked for proof. They demanded rigor. They needed randomized controlled trials.
They Called for Evidence. The Trials Came: Prasad, Marks, and the Return to RCTs
They Called for Evidence. The Trials Came: Prasad, Marks, and the Return to RCTs
They asked for proof. They demanded rigor. They needed randomized controlled trials.
Dr. Vinay Prasad spoke plain. "The establishment," he said, "must strive to get things right. They need to do studies. They need to be held to the highest standard." The line landed. It was a call for evidence. For hard answers.
Dr. Peter Marks answered. He moved policy and process. Trials followed. The debate became action. The question now is what that action means for patients, for policy, and for the future of evidence-based medicine.
Why RCTs Matter
Randomized controlled trials (RCTs) are the gold standard in clinical research. They cut bias. They test cause and effect. They tell us whether a drug, vaccine, or intervention truly works. In a noisy age, they provide clarity.
Without RCTs, medicine drifts on opinion and hope. With them, medicine stands on proof. That is why the call for RCTs matters. It is a demand for responsible public health.
Who Is Dr. Vinay Prasad
Prasad is a physician and a critic of weak evidence. He pushes for trials over assumptions. His point is sharp and simple: policy makers must prove their choices. They must test. They must publish.
Who Is Dr. Peter Marks
Marks leads a regulatory office with real power over vaccines and biologics. He holds the tools of approval. When he moves, trials can be prioritized and designed with signal and speed. When regulators act, the messy middle between science and policy can become cleaner.
How the Response Unfolded
A call met a system ready to act. Agencies adjusted processes. Sponsors and regulators aligned on trial questions. RCTs were planned or expedited. The work was technical. It was also moral.
This is not mere bureaucracy. It is stewardship. The body and the trust of the public deserve rigorous proof. That truth is simple. It is also hard.
What This Means for Patients and Policy
Patients gain clarity. Doctors gain data. Policy gains a backbone. Where before decisions rested on weak signals, now stronger evidence can guide practice. That reduces harm. It raises standards.
But trials take time. RCTs demand resources. They require honest endpoints and good design. Regulators must resist shortcuts. The public must accept that good evidence is not instant.
Lessons for Evidence-Based Medicine
- Demand trials, not anecdotes. RCTs remain the best tool for causal claims.
- Regulators must have the will and the systems to deliver timely trials.
- Trial design must be transparent and patient-centered.
- Results must be published and acted on.
Simple Steps Forward
Put trials at the start, not the end. Align incentives so sponsors and regulators design RCTs early. Fund trials that answer the questions clinicians and patients actually face. Measure what matters. Share the data.
A brief, moral note: the body is a trust. We are stewards. We must use evidence to honor that trust.
Conclusion
A clear call for RCTs met regulators who could deliver them. The result is stronger evidence. The work is not done. The demand for rigor must continue. Medicine is a craft and a duty. It grows only on proof.
Source: Jonathan Howard, December 19, 2025. Quote by Dr. Vinay Prasad.